Cover Image
市場調查報告書

tesa Labtec GmbH:產品平台分析

tesa Labtec GmbH - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 314189
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
tesa Labtec GmbH:產品平台分析 tesa Labtec GmbH - Product Pipeline Review - 2014
出版日期: 2014年09月15日 內容資訊: 英文 22 Pages
簡介

藥物輸送企業tesa Labtec GmbH對於製藥業界的藥物輸送技術之開發技術及生產能力都有卓越貢獻。該公司特別緻力於製造局部貼片和口服薄膜(Rapidfilm)。

本報告提供tesa Labtec GmbH 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

tesa Labtec GmbH的基本資料

  • tesa Labtec GmbH概要
  • 主要資訊
  • 企業資料

tesa Labtec GmbH:R&D概要

  • 主要的治療範圍

tesa Labtec GmbH:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

tesa Labtec GmbH:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

tesa Labtec GmbH:藥物簡介

  • acyclovir
  • donepezil hydrochloride
  • rasagiline

tesa Labtec GmbH:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

tesa Labtec GmbH:最近的開發平台趨勢

tesa Labtec GmbH:暫停中的計劃

tesa Labtec GmbH:總公司和子公司的所在地

附錄

圖表

目錄
Product Code: GMDHC06364CDB

Summary

Global Markets Direct's, 'tesa Labtec GmbH - Product Pipeline Review - 2014', provides an overview of the tesa Labtec GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of tesa Labtec GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of tesa Labtec GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of tesa Labtec GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the tesa Labtec GmbH's pipeline products

Reasons to buy

  • Evaluate tesa Labtec GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of tesa Labtec GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the tesa Labtec GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of tesa Labtec GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of tesa Labtec GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of tesa Labtec GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • tesa Labtec GmbH Snapshot
    • tesa Labtec GmbH Overview
    • Key Information
    • Key Facts
  • tesa Labtec GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • tesa Labtec GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • tesa Labtec GmbH - Pipeline Products Glance
    • tesa Labtec GmbH - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • tesa Labtec GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • tesa Labtec GmbH - Drug Profiles
    • acyclovir
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • donepezil hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rasagiline
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • tesa Labtec GmbH - Pipeline Analysis
    • tesa Labtec GmbH - Pipeline Products by Target
    • tesa Labtec GmbH - Pipeline Products by Route of Administration
    • tesa Labtec GmbH - Pipeline Products by Molecule Type
    • tesa Labtec GmbH - Pipeline Products by Mechanism of Action
  • tesa Labtec GmbH - Recent Pipeline Updates
  • tesa Labtec GmbH - Dormant Projects
  • tesa Labtec GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • tesa Labtec GmbH, Key Information
  • tesa Labtec GmbH, Key Facts
  • tesa Labtec GmbH - Pipeline by Indication, 2014
  • tesa Labtec GmbH - Pipeline by Stage of Development, 2014
  • tesa Labtec GmbH - Monotherapy Products in Pipeline, 2014
  • tesa Labtec GmbH - Phase I, 2014
  • tesa Labtec GmbH - Preclinical, 2014
  • tesa Labtec GmbH - Pipeline by Target, 2014
  • tesa Labtec GmbH - Pipeline by Route of Administration, 2014
  • tesa Labtec GmbH - Pipeline by Molecule Type, 2014
  • tesa Labtec GmbH - Pipeline Products by Mechanism of Action, 2014
  • tesa Labtec GmbH - Recent Pipeline Updates, 2014
  • tesa Labtec GmbH - Dormant Developmental Projects,2014
  • tesa Labtec GmbH, Other Locations

List of Figures

  • tesa Labtec GmbH - Pipeline by Top 10 Indication, 2014
  • tesa Labtec GmbH - Pipeline by Stage of Development, 2014
  • tesa Labtec GmbH - Monotherapy Products in Pipeline, 2014
  • tesa Labtec GmbH - Pipeline by Top 10 Target, 2014
  • tesa Labtec GmbH - Pipeline by Top 10 Route of Administration, 2014
  • tesa Labtec GmbH - Pipeline by Top 10 Molecule Type, 2014
  • tesa Labtec GmbH - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top